Deprescribing should be performed in patients with advanced dementia (GDS ≥6), patients who have experienced adverse events or interactions, and patients who do not benefit from the treatment. The lack of consensus as to when and how to deprescribe anti-dementia drugs show the need for a guide to deprescribing anti-dementia drugs. A set of technical and ethical considerations should be taken into account in the prescribing/deprescribing process. Decisions surrounding deprescribing should be conducted as shared decision making with the patients and/or their caregivers ensuring that they are duly informed..

Authors:

- Amaya Echeverría

- Belén González

- Nuria Goñi

- Ana Rosa Gómez

    On behalf of the Working Group for Deprescription in Dementia of SNS-O